Hemostemix And FireFly Neuroscience's Brain Network Analytics Engage To Complete Phase 1 Vascular Dementia Clinical Trial Of ACP-01

Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASDAQ:AIFF) ("Firefly"), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders.

Hemostemix and Firefly will study brain wave activity in up to 100 patients before and after treatment with ACP-01 at baseline, 3-months, and 6-months post-treatment (the "Phase 1").

Hemostemix's Phase 1 clinical trial of vascular dementia is in line with Firefly's collaborations with globally recognized companies, such as Bright Minds, Novartis and Takeda. Through the collaboration, Hemostemix will leverage Firefly's proprietary database of 77,000 EEG brain scans across twelve disorders. Hemostemix and FireFly will work together to generate an exploratory endpoint to objectively prove that intrathecal injection of ACP-01 is a safe, preliminarily efficacious, and clinically relevant treatment for vascular dementia.